Retinal Biologics Market Outlook (2022 to 2028)

Retinal biologics market revenue totaled USD 19.96 Billion in 2021. The global market is expected to reach USD 41.92 Billion by 2028, surging at a CAGR of 11.1% over the period of 2022 to 2028.

Attribute Details
Retinal Biologics Market Size (2022) USD 22.25 Billion
Sales Forecast (2028) USD 41.92 Billion
Global Market Growth Rate (2022 to 2028) 11.1% CAGR
Share of Top 5 Players 50%

Retinal biologics accounted for 6.9% share of the global biologic therapeutics market in 2021.

How The Market Progressed Till June 2022?

Particulars Details
H1, 2021 11.08%
H1, 2022 Projected 11.14%
H1, 2022 Outlook 10.94%
BPS Change - H1, 2022 (O) - H1, 2022 (P) (-) 20 ↓
BPS Change - H1, 2022 (O) - H1, 2021 (-) 14 ↓

According to Future Market Insights' analysis, the global retinal biologics market expects to drop by 14 Basis Point Share (BPS) in H1-2022 as compared to H1-2021. Whereas in comparison to H1-2022 Projected value, the market during H1-2022 outlook period will show a dip of 20 BPS.

The availability of very few retinal biologics, their severe side effects, rigorous regulatory standards involved with obtaining biologics approvals, and the exorbitant cost of effective drugs and biologics are all contributing factors to the drop in BPS values.

The market will however witness a positive growth outlook over the forecast period, owed to the increasing intensive research activities for the production of novel biologics for novel disease therapeutics.

The key development in the market includes innovations in ocular drug delivery to the retina with the development of intravitreal drugs. The retinal biologics market is subject to macroeconomic and industrial factors in accordance to stringent regulatory standards and approval activities for biologics.

Demand Analysis Of Retinal Biologics From 2013 to 2021 Vs Future Market Outlook For 2022 to 2028

Rising Burden of Retinal Diseases to Boost Overall Market Growth

From 2013 to 2021, the global retinal biologics market registered significant gains, experiencing a CAGR worth 10.2%

Retinal biologics are bioengineered molecules that are implanted inside the eyes to heal chronic retinal diseases. Biologics are generally produced from living organisms such as microorganisms, or animal or plant cells. Some of the retinal biologics used for retinal diseases are Eylea, Lucentis, Humira, Macugen, and others.

Increased frequency of retinal diseases such as age-related macular degeneration around the world is driving the market expansion. According to WHO statistics, nearly 2.2 billion individuals worldwide suffer from near or distance vision impairment. As the prevalence of vision impairment rises, the need for effective therapeutic alternatives, such as retinal biologics, is rising as well.

Retinal biologics are a new class of medications that target specific markers in the patient's body to alleviate the symptoms of a variety of systemic or ocular disorders that present in the eye.

Considering these factors, the market is projected to witness high growth over the forecast period, registering an impressive CAGR of 11.1% to reach USD 41.92 Billion by 2028.

What Are The Major Factors Driving Retinal Biologics Market Growth?

Rising R&D Activities in Retinal Gene Therapies to Fuel Market Expansion

The market will be driven by a strong focus on R&D connected with retinal gene therapies conducted by different institutes, biologics firms, and innovative product releases by prominent market participants in the form of biologics and implants. Efforts to develop a complementary therapeutic treatment will boost the market growth.

Market Growth Complemented by Increasing Burden of Retinal Diseases

Diabetic retinopathy has been a rising concern as the disease leads to vision loss among type I and type II adult diabetic patients. Diabetic macular edema also results from the consequences of diabetic retinopathy, which leads to the swelling of the macula. Moreover, increasing burden of other retinal diseases such as uveitis and orbital inflammation is another factor surging demand for retinal drugs and biologics.

Retinal gene therapy is a therapeutic approach wherein inherited defective genes are replaced by treatment with DNA or RNA. Retinal gene therapy is considered to be a significant approach as there occurs less contamination, and the viral vector can easily accommodate within the eyes.

What Are The Key Restraints Towards The Retinal Biologics Market Growth?

Regulatory Obstructions Likely to Hinder Demand for Retinal Biologics

Limited availability of retinal biologics, hazardous biologic side effects, and limited access for retinal biologics and efficient treatments due to higher costs are restraining the market growth.

The market is being challenged by the side effects of retinal biologics, which include retinal tear, sickness, and eye pain. Governing authorities' strict regulatory compliances associated with biologics approval are impeding industry growth.

How Is North America Propelling Demand For Retinal Biologics?

Ongoing Advancements in Biologics for Retinal Treatment

North America is expected to have a significant share in the global retinal biologics market. Continuous improvements in healthcare infrastructure, as well as an increase in the number of cases of retinal illnesses and favorable reimbursement policies, are expected to promote market expansion in the region.

Prominent presence of key manufacturers and increased healthcare spending are driving market growth in the region. Growing diabetes population is a major driver in the development of biologics for retinal treatment in North America.

Country-Wise Analysis

Why is the USA Retinal Biologics Market Growing at a Rapid Pace?

Increased Prevalence of Diabetic Macular Edema to Augment Demand for Retinal Biologics

Diabetic retinopathy is a disease that affects people who have diabetes. Diabetic retinopathy is the major cause of new incidents of blindness in adults aged 20 to 74 years in the United States.

According to a new research study released by the Centers for Disease Control and Prevention, more than 100 million persons in the United States currently have diabetes or prediabetes.

In addition, researchers are working on innovative strategies to treat diabetic macular edema. As a result, rising R&D spending in the country as well as risk factors that contribute to disease development will have an impact on the retinal biologics market in the USA over the forecast period.

What is the Demand Outlook for Retinal Biologics in China?

Rising Efforts for Development of Retinal Drugs to Drive Market Growth.

The market in China is expected to grow due to rapidly rising cases of uveitis, diabetic retinopathy, and macular degeneration. Diabetes is exacerbated by a shift in lifestyle and an increase in bad eating habits, as a result of these factors, the global market for retinal drugs and biologics is expected to expand significantly.

Along with increasing incidence of eye diseases, there are a growing number of research initiatives focused on retinal drugs. Furthermore, growing geriatric population, which is becoming a target patient pool for retinal biologics, will boost market growth in China.

Category-Wise Insights

Which Drug Class is Projected to Get Traction in Retinal Biologics?

VEGF-A Antagonists Most Preferred as They are Largely Tolerated & Give Instant Results to Eye Disorders.

VEGF-A antagonists are used to treat eye damage and enhance corneal wound healing. The global retinal biologics market is also expected to be fueled by the rising prevalence of other retinal illnesses such as orbital inflammation and uveitis.

VEGF-A antagonists are commonly given for the treatment of diabetic retinopathy and diabetic macular edema. In the case of non-infectious uveitis, it is seen to be the ideal alternative to typical suppressing treatments.

Many firms have focused on VEGF-A antagonists because they reduce angiogenesis. Manufacturers are investing in the development of retinal biologics in a similar field due to the widespread acceptance of VEGF-A antagonist therapy.

Which Indication Dominates Retinal Biologics Demand Growth?

Increasing Adoption of Retinal Biologics for Macular Degeneration Treatment

Macular degeneration indication is expected to account 36.9% share of the retinal biologics market in 2022. Macular Degeneration is a vision loss condition that affects the macula.

Despite the availability of improved treatment alternatives, the global retinal biologics market is likely to benefit from the increased prevalence of macular degeneration. According to the American Macular Degeneration Foundation, the prevalence is higher than the combined rates of cataracts and glaucoma in over 10 million Americans (AMDF).

Because macular degeneration primarily affects adults aged 50 and over, the prevalence of MD continues to go up, despite improving treatment choices, as the population ages.

Competitive Landscape

Several companies are entering into licensing and collaboration agreements to expand their products into various countries across the world to cater to unmet demand. Leading market players are concentrating their efforts on research & development to discover new medications and improve treatment options.

For instance,

  • In 2021, SemaThera Inc. and Roche established a multi-year research and licensing relationship to expand SemaThera's novel biologics portfolio for the treatment of ischemic retinal illnesses such as diabetic retinopathy.

Retinal Biologics Industry Report Scope

Attribute Details
Forecast Period 2022 to 2028
Historical Data Available for 2013 to 2021
Market Analysis Value in USD Million
Key Regions Covered North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA)
Key Countries Covered USA, Canada, Mexico, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Nordic, Spain, Japan, China, India, Malaysia, Thailand, Australia, GCC Countries, South Africa, Turkey
Key Market Segments Covered Drug Class, Indication, Distribution Channel, Region
Key Companies Profiled Spark Therapeutics, Inc.; F. Hoffmann-La Roche Ltd.; Regeneron Pharmaceuticals, Inc.; AbbVie Inc.; Amgen Inc.; Novartis Pharma AG; MeiraGTx Limited; Oxurion NV; Santen Pharmaceutical Co., Ltd.; Bayer AG; Bausch Health Companies Inc.; Merck & Co., Inc.
Pricing Available upon Request

Key Segments of Retinal Biologics Industry Survey

Retinal Biologics Market by Drug Class:

  • VEGF-A Antagonists
  • TNF-α Inhibitors

Retinal Biologics Market by Indication:

  • Macular Degeneration
  • Diabetic Macular Edema
  • Diabetic Retinopathy
  • Uveitis
  • Others

Retinal Biologics Market by Distribution Channel:

  • Institutional Sales
  • Retail Pharmacies
  • Mail Order Pharmacies
  • Retail Sales

Retinal Biologics Market by Region:

  • North America Retinal Biologics Market
  • Latin America Retinal Biologics Market
  • Europe Retinal Biologics Market
  • East Asia Retinal Biologics Market
  • South Asia & Pacific Retinal Biologics Market
  • Middle East & Africa (MEA) Retinal Biologics Market

Table of Content

  • 1. Executive Summary
  • 2. Market Introduction
  • 3. Global Economic Outlook
  • 4. Market Opportunity Analysis
  • 5. Market Dynamics
  • 6. Key Inclusion
  • 7. North America Market Analysis 2013 to 2021 and Forecast 2022 to 2028
  • 8. Latin America Market Analysis 2013 to 2021 and Forecast 2022 to 2028
  • 9. Western Europe Market Analysis 2013 to 2021 and Forecast 2022 to 2028
  • 10. Eastern Europe Market Analysis 2013 to 2021 and Forecast 2022 to 2028
  • 11. Asia Pacific Excluding Japan Market Analysis 2013 to 2021 and Forecast 2022 to 2028
  • 12. Japan Market Analysis 2013 to 2021 and Forecast 2022 to 2028
  • 13. Middle East and Africa Market Analysis 2013 to 2021 and Forecast 2022 to 2028
  • 14. Forecast Factors: Relevance and Impact
  • 15. Forecast Assumptions
  • 16. Competition Analysis
    • 16.1. Spark Therapeutics Inc.
    • 16.2. F. Hoffmann-La Roche Ltd
    • 16.3. Regeneron Pharmaceuticals, Inc.
    • 16.4. AbbVie Inc
    • 16.5. Johnson & Johnson Services, Inc
    • 16.6. Amgen Inc.
  • 17. Global Market Analysis 2013 to 2021 and Forecast 2022 to 2028 by Region
    • 17.1. North America
    • 17.2. Latin America
    • 17.3. Western Europe
    • 17.4. Eastern Europe
    • 17.5. Asia Pacific Excluding Japan
    • 17.6. Japan
    • 17.7. Middle East and Africa
  • 18. Global Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Drug Class
    • 18.1. VEGF-A antagonist
    • 18.2. TNF-α inhibitor
  • 19. Global Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Indication
    • 19.1. Macular degeneration
    • 19.2. Diabetic Retinopathy
    • 19.3. Diabetic Macular Edema
    • 19.4. Uveitis
    • 19.5. Others
  • 20. Global Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Distributional Channel
    • 20.1. Institutional Sales
      • 20.1.1. Specialty Clinics
      • 20.1.2. Hospitals
    • 20.2. Retail Sales
      • 20.2.1. Retail Pharmacies
      • 20.2.2. Mail Order Pharmacies
  • 21. Global Market Analysis 2013 to 2021 and Forecast 2022 to 2028
  • 22. Assumptions and Acronyms Used
  • 23. Research Methodology

List of Tables

Table 01: Expenditure on Health, (% of GDP), by Country, 2013 - 2021

Table 02: Expenditure on Health, (% of GDP), by Country, 2013 - 2021

Table 03: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 04: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class

Table 05: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication

Table 06: North America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 07: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 08: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class

Table 09: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication

Table 10: Latin America Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 11: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 12: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class

Table 13: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication

Table 14: Western Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 15: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 16: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class

Table 17: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication

Table 18: Eastern Europe Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 19: Asia Pacific Excluding Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 20: Asia Pacific Excluding Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class

Table 21: Asia Pacific Excluding Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication

Table 22: Asia Pacific Excluding Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 23: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class

Table 24: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication

Table 25: Japan Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 26: Middle East and Africa Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country

Table 27: Middle East and Africa Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class

Table 28: Middle East and Africa Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication

Table 29: Middle East and Africa Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Table 30: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Region

Table 31: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class

Table 32: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication

Table 33: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

List of Figures

Figure 1: Global Market Value (US$ Mn), by Regions

Figure 2: Global Market Value Share By Drug Class (2021)

Figure 3: Global Market Value Share By Indication (2021)

Figure 4: Global Market Value Share By Distributional Channel

Figure 5: Global Healthcare Expenditure in US$ Tn (2013–2021)

Figure 6: North America Market Size (US$ Mn) Analysis, 2013–2021

Figure 7: North America Market Size (US$ Mn) & Y-o-Y Growth (%),

Figure 8: North America Market Analysis by Country –2022 & 2028

Figure 9: North America Market Y-o-Y Growth Projections by Country, 2022 – 2028

Figure 10: North America Market Attractiveness Analysis by Country, 2022 – 2028

Figure 11: North America Market Analysis by Drug Class–2022 & 2028

Figure 12: North America Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028

Figure 13: North America Market Attractiveness Analysis by Drug Class, 2022 – 2028

Figure 14: North America Market Analysis by Indication–2022 & 2028

Figure 15: North America Market Y-o-Y Growth Projections by Indication, 2022 – 2028

Figure 16: North America Market Attractiveness Analysis by Indication, 2022 – 2028

Figure 17: North America Market Analysis by Distribution Channel–2022 & 2028

Figure 18: North America Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028

Figure 19: North America Market Attractiveness Analysis by Distribution Channel, 2022 – 2028

Figure 20: Latin America Market Size (US$ Mn) Analysis, 2013–2021

Figure 21: Latin America Market Size (US$ Mn) & Y-o-Y Growth (%),

Figure 22: Latin America Market Analysis by Country –2022 & 2028

Figure 23: Latin America Market Y-o-Y Growth Projections by Country, 2022 – 2028

Figure 24: Latin America Market Attractiveness Analysis by Country, 2022 – 2028

Figure 25: Latin America Market Analysis by Drug Class–2022 & 2028

Figure 26: Latin America Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028

Figure 27: Latin America Market Attractiveness Analysis by Drug Class, 2022 – 2028

Figure 28: Latin America Market Analysis by Indication–2022 & 2028

Figure 29: Latin America Market Y-o-Y Growth Projections by Indication, 2022 – 2028

Figure 30: Latin America Market Attractiveness Analysis by Indication, 2022 – 2028

Figure 31: Latin America Market Analysis by Distribution Channel–2022 & 2028

Figure 32: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028

Figure 33: Latin America Market Attractiveness Analysis by Distribution Channel, 2022 – 2028

Figure 34: Western Europe Market Size (US$ Mn) Analysis, 2013–2021

Figure 35: Western Europe Market Size (US$ Mn) & Y-o-Y Growth (%),

Figure 36: Western Europe Market Analysis by Country –2022 & 2028

Figure 37: Western Europe Market Y-o-Y Growth Projections by Country, 2022 – 2028

Figure 38: Western Europe Market Attractiveness Analysis by Country, 2022 – 2028

Figure 39: Western Europe Market Analysis by Drug Class–2022 & 2028

Figure 40: Western Europe Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028

Figure 41: Western Europe Market Attractiveness Analysis by Drug Class, 2022 – 2028

Figure 42: Western Europe Market Analysis by Indication–2022 & 2028

Figure 43: Western Europe Market Y-o-Y Growth Projections by Indication, 2022 – 2028

Figure 44: Western Europe Market Attractiveness Analysis by Indication, 2022 – 2028

Figure 45: Western Europe Market Analysis by Distribution Channel–2022 & 2028

Figure 46: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028

Figure 47: Western Europe Market Attractiveness Analysis by Distribution Channel, 2022 – 2028

Figure 48: Eastern Europe Market Size (US$ Mn) Analysis, 2013–2021

Figure 49: Eastern Europe Market Size (US$ Mn) & Y-o-Y Growth (%),

Figure 50: Eastern Europe Market Analysis by Country –2022 & 2028

Figure 51: Eastern Europe Market Y-o-Y Growth Projections by Country, 2022 – 2028

Figure 52: Eastern Europe Market Attractiveness Analysis by Country, 2022 – 2028

Figure 53: Eastern Europe Market Analysis by Drug Class–2022 & 2028

Figure 54: Eastern Europe Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028

Figure 55: Eastern Europe Market Attractiveness Analysis by Drug Class, 2022 – 2028

Figure 56: Eastern Europe Market Analysis by Indication–2022 & 2028

Figure 57: Eastern Europe Market Y-o-Y Growth Projections by Indication, 2022 – 2028

Figure 58: Eastern Europe Market Attractiveness Analysis by Indication, 2022 – 2028

Figure 59: Eastern Europe Market Analysis by Distribution Channel–2022 & 2028

Figure 60: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028

Figure 61: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2022 – 2028

Figure 62: Asia Pacific Excluding Japan Market Size (US$ Mn) Analysis, 2013–2021

Figure 63: Asia Pacific Excluding Japan Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 64: Asia Pacific Excluding Japan Market Analysis by Country –2022 & 2028

Figure 65: Asia Pacific Excluding Japan Market Y-o-Y Growth Projections by Country, 2022 – 2028

Figure 66: Asia Pacific Excluding Japan Market Attractiveness Analysis by Country, 2022 – 2028

Figure 67: Asia Pacific Excluding Japan Market Analysis by Drug Class–2022 & 2028

Figure 68: Asia Pacific Excluding Japan Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028

Figure 69: Asia Pacific Excluding Japan Market Attractiveness Analysis by Drug Class, 2022 – 2028

Figure 70: Asia Pacific Excluding Japan Market Analysis by Indication–2022 & 2028

Figure 71: Asia Pacific Excluding Japan Market Y-o-Y Growth Projections by Indication, 2022 – 2028

Figure 72: Asia Pacific Excluding Japan Market Attractiveness Analysis by Indication, 2022 – 2028

Figure 73: Asia Pacific Excluding Japan Market Analysis by Distribution Channel–2022 & 2028

Figure 74: Asia Pacific Excluding Japan Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028

Figure 75: Asia Pacific Excluding Japan Market Attractiveness Analysis by Distribution Channel, 2022 – 2028

Figure 76: Japan Market Size (US$ Mn) Analysis, 2013–2021

Figure 77: Japan Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 78: Japan Market Analysis by Drug Class–2022 & 2028

Figure 79: Japan Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028

Figure 80: Japan Market Attractiveness Analysis by Drug Class, 2022 – 2028

Figure 81: Japan Market Analysis by Indication–2022 & 2028

Figure 82: Japan Market Y-o-Y Growth Projections by Indication, 2022 – 2028

Figure 83: Japan Market Attractiveness Analysis by Indication, 2022 – 2028

Figure 84: Japan Market Analysis by Distribution Channel–2022 & 2028

Figure 85: Japan Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028

Figure 86: Japan Market Attractiveness Analysis by Distribution Channel, 2022 – 2028

Figure 87: Middle East and Africa Market Size (US$ Mn) Analysis, 2013–2021

Figure 88: Middle East and Africa Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 89: Middle East and Africa Market Analysis by Country –2022 & 2028

Figure 90: Middle East and Africa Market Y-o-Y Growth Projections by Country, 2022 – 2028

Figure 91: Middle East and Africa Market Attractiveness Analysis by Country, 2022 – 2028

Figure 92: Middle East and Africa Market Analysis by Drug Class–2022 & 2028

Figure 93: Middle East and Africa Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028

Figure 94: Middle East and Africa Market Attractiveness Analysis by Drug Class, 2022 – 2028

Figure 95: Middle East and Africa Market Analysis by Indication–2022 & 2028

Figure 96: Middle East and Africa Market Y-o-Y Growth Projections by Indication, 2022 – 2028

Figure 97: Middle East and Africa Market Attractiveness Analysis by Indication, 2022 – 2028

Figure 98: Middle East and Africa Market Analysis by Distribution Channel–2022 & 2028

Figure 99: Middle East and Africa Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028

Figure 100: Middle East and Africa Market Attractiveness Analysis by Distribution Channel, 2022 – 2028

Figure 101: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Region

Figure 102: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class

Figure 103: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication

Figure 104: Global Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel

Figure 105: Global Market Size (US$ Mn) Analysis, 2013–2021

Figure 106: Global Market Size (US$ Mn) & Y-o-Y Growth (%),

Figure 107: Global Market Absolute $ Opportunity, 2013–2028

Frequently Asked Questions

What is the estimated growth rate of the global retinal biologics market?

The global retinal biologics market is estimated to exhibit a CAGR of 11.1% during the forecast period (2022 to 2028).

Which segment has the largest share in retinal biologics?

Macular degeneration accounts for 36.9% share of the retinal biologics market.

What is the projected market value for retinal biologics?

The global retinal biologics market is expected to reach a valuation of USD 41.92 Billion by 2028.

What key trends are driving growth of the retinal biologics market?

Increasing prevalence of diabetic eye diseases and significant R&D investments for developing biologics are key trends driving market growth.

Which are the top companies in the retinal biologics market?

Major players operating in the market include Spark Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., AbbVie Inc., and Amgen Inc.

Explore Similar Insights

Future Market Insights

Retinal Biologics Market